Baidu
map

Brain:脑影像学进展确定阿兹海默症传播发展的关键蛋白,老年痴呆有救了

2018-01-08 佚名 medicalxpress

最近在脑成像方面的进展首次表明,在阿尔茨海默氏病中,一种导致神经细胞死亡的关键蛋白在整个大脑中传播,因此阻止它的传播有望阻止这种疾病的蔓延。


PET scan of a human brain with Alzheimer's disease. Credit: public domain

最近在脑成像方面的进展首次表明,在阿尔茨海默氏病中,一种导致神经细胞死亡的关键蛋白在整个大脑中传播,因此阻止它的传播有望阻止这种疾病的蔓延。

据估计,全世界有四千四百万人患有阿尔茨海默病,这种疾病的症状包括记忆力问题、行为改变和逐渐丧失独立性。这些症状是由大脑中两种异常蛋白质的积累引起的:淀粉样β蛋白和τ蛋白。人们认为淀粉样β首先发生,鼓励了τ的出现和传播,而正是后者破坏了神经细胞,吞噬了我们的记忆和认知功能。

直到几年前,只有在验尸后,才能通过检查已经死亡的阿尔茨海默氏症患者的大脑来观察这些蛋白质的积累。然而,正电子发射断层扫描(PET)的最新进展使科学家们能够开始对仍然活着的病人进行成像:病人被注射放射性配体,这是一种与目标结合的示踪分子(τ),可以用PET扫描仪检测。

发表在《大脑》杂志上的一项研究中,剑桥大学的科学家们领导的一个研究小组描述了一种结合成像技术的方法,研究了17例阿尔茨海默氏病患者的τ模式与大脑连线的关系。科学家们一直在猜测着τ在整个大脑中的具体表现。一种假设是有害的τ从一个地方开始,然后扩散到其他地区,引发连锁反应,这种称为“跨神经元传播”的观点得到了小鼠研究的支持。当一只老鼠被注射异常的人类τ时,蛋白质在整个大脑中迅速传播;然而,这一证据是有争议的,因为比在人脑中观察到的τ含量高得多,注射的τ的数量要高得多。这种蛋白质在小鼠大脑中迅速传播,而在人脑中缓慢传播。

还有另外两个相互竞争的假设。“代谢易损性”假说显示,τ是在神经细胞中局部制造的,但有些区域有较高的代谢需求,因此更容易受到这种蛋白质的影响。在这些情况下,τ是细胞窘迫的标志。

第三个假说是“营养支持”,也表明一些大脑区域比其他区域更易受伤害,但这与代谢需求无关,更多地与区域缺乏营养或基因表达模式有关。由于PET扫描技术的发展,现在可以比较这些假设了。

研究人员表示:“五年前,这种研究是不可能的,但由于成像的最新进展,我们可以检验这些假设符合我们所观察到的。”科学家们研究了老年痴呆症患者大脑的功能连接,换句话说,他们的大脑是如何连接起来的,并将其与tau蛋白水平进行比较。他们的研究结果支持跨神经元传播理念。

“如果跨神经传播的理念是正确的,那么大脑区域是最高度连接的,这和我们在流感中所看到的一样,例如,拥有最大区域的人最容易染上流感,然后传染给其他人。这正是我们看到的。”

“在阿尔茨海默病,头为最常见的脑区,首先出现内嗅皮质区是旁边的海马,“记忆区”。这就是为什么老年痴呆症最早的症状往往是记忆问题。但是我们的研究表明tau蛋白会扩散到大脑,感染和破坏神经细胞,从而使患者的症状变得越来越严重。跨神经蔓延假说的验证是非常重要的,因为它意味着我们可能会减慢或通过阻止tau蛋白,可以使用沿着神经元的药物来阻止阿尔茨海默病的进展。”

该研究小组还调查了17例患者的另一种形式的痴呆症影响,被称为进行性核上性麻痹(PSP),一种罕见的疾病,会影响平衡,视觉和语音,但没有记忆。在PSP患者中,tau蛋白倾向于在大脑的底部而不是在整个脑内。研究人员发现,这些患者tau蛋白积聚的模式支持了第二个假设,即代谢脆弱性和营养支持,而不是tau扩散到大脑的想法。

研究人员还将患者纳入疾病的不同阶段,研究tau蛋白积聚如何影响大脑的连接。在阿尔茨海默氏症患者中,他们发现,随着tau的形成和损伤网络,连接变得更加随机,这有助于解释这种病人典型的混乱和混乱的记忆。

在PSP中,健康个体携带大部分信息的“高速公路”受到的损害最大,这意味着信息需要沿着更间接的路线在大脑中传播。这可能解释了为什么当被问到一个问题时,PSP患者可能反应迟缓,但最终会得到正确的答案。

原始出处:

Thomas E Cope, Timothy Rittman, Robin J Borchert, et.al. Tau burden and the functional connectome in Alzheimer’s disease and progressive supranuclear palsy. Brain 05 January 2018

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1957341, encodeId=367e195e34109, content=<a href='/topic/show?id=99275029242' target=_blank style='color:#2F92EE;'>#影像学进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50292, encryptionId=99275029242, topicName=影像学进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sat Aug 25 22:13:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027616, encodeId=968e202e61696, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Wed Oct 24 10:13:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278757, encodeId=4bc72e875778, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Mon Jan 15 15:58:26 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277750, encodeId=ab112e77507d, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Jan 12 08:21:09 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465348, encodeId=a05a146534896, content=<a href='/topic/show?id=78829e719a0' target=_blank style='color:#2F92EE;'>#阿兹海默症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97719, encryptionId=78829e719a0, topicName=阿兹海默症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e96710983, createdName=jiekemin, createdTime=Tue Jan 09 23:13:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276765, encodeId=8b8a2e676595, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Jan 09 06:46:41 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276573, encodeId=53b72e657391, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Jan 08 08:55:29 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276567, encodeId=17672e656756, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Mon Jan 08 08:45:18 CST 2018, time=2018-01-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1957341, encodeId=367e195e34109, content=<a href='/topic/show?id=99275029242' target=_blank style='color:#2F92EE;'>#影像学进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50292, encryptionId=99275029242, topicName=影像学进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sat Aug 25 22:13:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027616, encodeId=968e202e61696, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Wed Oct 24 10:13:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278757, encodeId=4bc72e875778, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Mon Jan 15 15:58:26 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277750, encodeId=ab112e77507d, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Jan 12 08:21:09 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465348, encodeId=a05a146534896, content=<a href='/topic/show?id=78829e719a0' target=_blank style='color:#2F92EE;'>#阿兹海默症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97719, encryptionId=78829e719a0, topicName=阿兹海默症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e96710983, createdName=jiekemin, createdTime=Tue Jan 09 23:13:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276765, encodeId=8b8a2e676595, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Jan 09 06:46:41 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276573, encodeId=53b72e657391, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Jan 08 08:55:29 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276567, encodeId=17672e656756, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Mon Jan 08 08:45:18 CST 2018, time=2018-01-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1957341, encodeId=367e195e34109, content=<a href='/topic/show?id=99275029242' target=_blank style='color:#2F92EE;'>#影像学进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50292, encryptionId=99275029242, topicName=影像学进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sat Aug 25 22:13:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027616, encodeId=968e202e61696, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Wed Oct 24 10:13:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278757, encodeId=4bc72e875778, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Mon Jan 15 15:58:26 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277750, encodeId=ab112e77507d, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Jan 12 08:21:09 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465348, encodeId=a05a146534896, content=<a href='/topic/show?id=78829e719a0' target=_blank style='color:#2F92EE;'>#阿兹海默症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97719, encryptionId=78829e719a0, topicName=阿兹海默症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e96710983, createdName=jiekemin, createdTime=Tue Jan 09 23:13:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276765, encodeId=8b8a2e676595, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Jan 09 06:46:41 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276573, encodeId=53b72e657391, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Jan 08 08:55:29 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276567, encodeId=17672e656756, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Mon Jan 08 08:45:18 CST 2018, time=2018-01-08, status=1, ipAttribution=)]
    2018-01-15 三生有幸9135

    学习一下谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1957341, encodeId=367e195e34109, content=<a href='/topic/show?id=99275029242' target=_blank style='color:#2F92EE;'>#影像学进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50292, encryptionId=99275029242, topicName=影像学进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sat Aug 25 22:13:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027616, encodeId=968e202e61696, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Wed Oct 24 10:13:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278757, encodeId=4bc72e875778, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Mon Jan 15 15:58:26 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277750, encodeId=ab112e77507d, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Jan 12 08:21:09 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465348, encodeId=a05a146534896, content=<a href='/topic/show?id=78829e719a0' target=_blank style='color:#2F92EE;'>#阿兹海默症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97719, encryptionId=78829e719a0, topicName=阿兹海默症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e96710983, createdName=jiekemin, createdTime=Tue Jan 09 23:13:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276765, encodeId=8b8a2e676595, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Jan 09 06:46:41 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276573, encodeId=53b72e657391, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Jan 08 08:55:29 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276567, encodeId=17672e656756, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Mon Jan 08 08:45:18 CST 2018, time=2018-01-08, status=1, ipAttribution=)]
    2018-01-12 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1957341, encodeId=367e195e34109, content=<a href='/topic/show?id=99275029242' target=_blank style='color:#2F92EE;'>#影像学进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50292, encryptionId=99275029242, topicName=影像学进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sat Aug 25 22:13:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027616, encodeId=968e202e61696, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Wed Oct 24 10:13:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278757, encodeId=4bc72e875778, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Mon Jan 15 15:58:26 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277750, encodeId=ab112e77507d, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Jan 12 08:21:09 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465348, encodeId=a05a146534896, content=<a href='/topic/show?id=78829e719a0' target=_blank style='color:#2F92EE;'>#阿兹海默症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97719, encryptionId=78829e719a0, topicName=阿兹海默症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e96710983, createdName=jiekemin, createdTime=Tue Jan 09 23:13:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276765, encodeId=8b8a2e676595, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Jan 09 06:46:41 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276573, encodeId=53b72e657391, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Jan 08 08:55:29 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276567, encodeId=17672e656756, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Mon Jan 08 08:45:18 CST 2018, time=2018-01-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1957341, encodeId=367e195e34109, content=<a href='/topic/show?id=99275029242' target=_blank style='color:#2F92EE;'>#影像学进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50292, encryptionId=99275029242, topicName=影像学进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sat Aug 25 22:13:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027616, encodeId=968e202e61696, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Wed Oct 24 10:13:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278757, encodeId=4bc72e875778, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Mon Jan 15 15:58:26 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277750, encodeId=ab112e77507d, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Jan 12 08:21:09 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465348, encodeId=a05a146534896, content=<a href='/topic/show?id=78829e719a0' target=_blank style='color:#2F92EE;'>#阿兹海默症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97719, encryptionId=78829e719a0, topicName=阿兹海默症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e96710983, createdName=jiekemin, createdTime=Tue Jan 09 23:13:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276765, encodeId=8b8a2e676595, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Jan 09 06:46:41 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276573, encodeId=53b72e657391, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Jan 08 08:55:29 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276567, encodeId=17672e656756, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Mon Jan 08 08:45:18 CST 2018, time=2018-01-08, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1957341, encodeId=367e195e34109, content=<a href='/topic/show?id=99275029242' target=_blank style='color:#2F92EE;'>#影像学进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50292, encryptionId=99275029242, topicName=影像学进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sat Aug 25 22:13:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027616, encodeId=968e202e61696, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Wed Oct 24 10:13:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278757, encodeId=4bc72e875778, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Mon Jan 15 15:58:26 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277750, encodeId=ab112e77507d, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Jan 12 08:21:09 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465348, encodeId=a05a146534896, content=<a href='/topic/show?id=78829e719a0' target=_blank style='color:#2F92EE;'>#阿兹海默症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97719, encryptionId=78829e719a0, topicName=阿兹海默症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e96710983, createdName=jiekemin, createdTime=Tue Jan 09 23:13:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276765, encodeId=8b8a2e676595, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Jan 09 06:46:41 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276573, encodeId=53b72e657391, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Jan 08 08:55:29 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276567, encodeId=17672e656756, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Mon Jan 08 08:45:18 CST 2018, time=2018-01-08, status=1, ipAttribution=)]
    2018-01-08 Y—xianghai

    学习了新知识

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1957341, encodeId=367e195e34109, content=<a href='/topic/show?id=99275029242' target=_blank style='color:#2F92EE;'>#影像学进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50292, encryptionId=99275029242, topicName=影像学进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sat Aug 25 22:13:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027616, encodeId=968e202e61696, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Wed Oct 24 10:13:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278757, encodeId=4bc72e875778, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Mon Jan 15 15:58:26 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277750, encodeId=ab112e77507d, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Jan 12 08:21:09 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465348, encodeId=a05a146534896, content=<a href='/topic/show?id=78829e719a0' target=_blank style='color:#2F92EE;'>#阿兹海默症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97719, encryptionId=78829e719a0, topicName=阿兹海默症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e96710983, createdName=jiekemin, createdTime=Tue Jan 09 23:13:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276765, encodeId=8b8a2e676595, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Tue Jan 09 06:46:41 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276573, encodeId=53b72e657391, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Jan 08 08:55:29 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276567, encodeId=17672e656756, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Mon Jan 08 08:45:18 CST 2018, time=2018-01-08, status=1, ipAttribution=)]
    2018-01-08 1dd8c52fm63(暂无匿称)

    学习学习.继续关注

    0

相关资讯

Sci Rep:有了这项技术,阿尔兹海默病的进展尽在掌握之中!

特文特大学的科学家利用“拉曼”光学技术,现在可以生成受阿尔茨海默病影响的脑组织图像。图像还包括周边区域,已经显示出变化。

从电视剧《深夜食堂》海清发病看阿尔茨海默症病人,如何早期诊断和护理

讲到阿尔茨海默症可能很多读者还不是太熟悉,但要说到老年痴呆症,大家听说的就比较多了。阿尔茨海默症大多发生在老年期,但是不代表年纪轻轻就不会得,如剧中的海清饰演的年轻妈妈,就称早老性痴呆。这也是为什么现在大多数不用“老年痴呆症”去称呼这个病的原因。

Radiology:阿尔兹海默病患者松果体体积减小:回顾性横断面MRI研究

阿尔茨海默病(Alzheimer disease,AD),又叫老年性痴呆,是一种中枢神经系统变性病,起病隐袭,病程呈慢性进行性,是老年期痴呆最常见的一种类型。主要表现为渐进性记忆障碍、认知功能障碍、人格改变及语言障碍等神经精神症状,严重影响社交、职业与生活功能。AD的病因及发病机制尚未阐明,特征性病理改变为β淀粉样蛋白沉积形成的细胞外老年斑和tau蛋白过度磷酸化形成的神经细胞内神经原纤维缠结,以及

阿尔茨海默病协会在美推生活方式干预试验

阿尔茨海默病协会(Alzheimer's Association)今天宣布推出一项投资达2000万美元的两年期临床试验,检验多维生活方式干预是否能够预防认知衰退和痴呆,试验对象为2500名目前没有认知方面疾病症状但后期认知衰退风险会增加的老年人。这项公告在2017年伦敦阿尔茨海默病协会国际会议(AAIC 2017)上做出。这项通过生活方式干预降低风险从而实现保护的大型美国试验(简称US POI

Cell Reprots:MIT大神科学家蔡理慧在神经修复领域取得新突破,有望找回阿尔兹海默病患者失去的记忆

记忆是人类适应其生存环境所需要的最基本能力,也是人们最宝贵的财富。然而,每年有许许多多的人因为阿尔兹海默病(AD)或者意外事故而丧失记忆,对患者以及家人造成了严重的影响。那么有没有办法帮助这些人恢复丧失的记忆呢?

重 Cell:揭示阿尔兹海默病新机制,大脑“清洁工”能量不足,无法清除蛋白斑

TREM2是小胶质细胞表明的一种受体,与阿茨海默病密切相关。携带TREM2特定突变的人患AD的风险高了五倍。近日,一项发表于Cell上的新研究发现,TREM2的高风险突变会导致小胶质细胞能量赤字。当这些细胞在能量亏空情况下工作时,它们无法保护神经元免受蛋白斑的损伤。

Baidu
map
Baidu
map
Baidu
map